Novavax, Inc. and Cadila Pharmaceuticals have announced the launch of their jointventure in India under the agreement signed between the two companies in March2009. This joint venture, called CPL Biologicals Pvt. Ltd., will develop andmanufacture vaccines, biological therapeutics and diagnostics in India usingtechnology contributed from Novavax and Cadila Pharmaceuticals. In addition,CPL Biologicals will establish manufacturing facilities in India and develop,produce and sell products such as seasonal influenza vaccine and potentiallyother novel vaccines against dengue fever and chikungunya fever based onNovavax’s virus-like-particle (VLP) vaccine technology. CPL Biologicals alsoexpects to develop the pandemic H1N1 influenza vaccine candidate in India thatNovavax is developing in the United States. Mr. I. A. Modi, Chairman of CPL Biologicals, noted: “This joint venturerepresents an important strategic alliance for vaccine development andmanufacturing in India and uses unique and cutting-edge vaccine technology.Our vision is to be a leading provider of high quality, affordable vaccines,biological therapeutics and diagnostics through world-class research andinnovative manufacturing to address current and future global healthchallenges.” Rahul Singhvi, President and Chief Executive Officer of Novavax, stated:”We are excited to see the agreement with Cadila announced in March come tofruition with the official launch of CPL Biologicals today. We look forwardto a long and successful effort to bring important new vaccines and otherpharmaceutical products to the people of India.”
